Registered title, quoted from ClinicalTrials.gov
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Xiamen University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06581640, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
Inclusion criterion 2
Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
Inclusion criterion 3
Received other experimental drug treatments within the last 3 months;
Exclusion criterion 11
ECOG performance status score ≤2, KPS >60%;
Inclusion criterion 5
Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;
Exclusion criterion 2
Pregnant or nursing women, as well as women planning to become pregnant within the next six months;
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06581640, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-80 years, no gender restrictions;
- Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
- Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
- As judged by the investigator, the expected survival time is >3 months;
- ECOG performance status score ≤2, KPS >60%;
- The patient has good liver, kidney, heart, and lung function: ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L; creatinine clearance rate >30 mL/min; heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%;
- Peripheral blood lymphocyte absolute count ALC ≥0.5 ×10\^9/L, PLT >30×10\^9/L, Hb >80 g/L and has a single collection venous access, and there are no other contraindications for hematopoietic cell separation;
- Those with fertility must agree to use highly effective contraceptive methods;
- The subject or their legal guardian can understand and is willing to sign a written informed consent form voluntarily.
Exclusion Criteria:
- Pregnant or nursing women, as well as women planning to become pregnant within the next six months;
- Positive virology tests for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus;
- History of other tumors (except for those with skin or cervical in situ cancers that have been cured by radical treatment and show no evidence of disease activity);
- Previously received treatment targeting BCMA;
- Underwent autologous hematopoietic stem cell transplantation within the last 6 weeks;
- Presence of uncontrolled active bacterial or fungal infection;
- Allergic to research-related drugs or cell components;
- Presence of active autoimmune diseases;
- Currently have unstable or active ulcers or gastrointestinal bleeding;
- Unable to cooperate with treatment and efficacy evaluation due to mental or psychological disorders;
- Received other experimental drug treatments within the last 3 months;
- The researcher believes that for other reasons, the individual is not suitable for the clinical trial.
Quoted from ClinicalTrials.gov, NCT06581640, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06581640, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.